Abu-Elmagd K, Bronsther O, Jain A, Irish W, Ramos H, Marino I R, Dodson F, Selby R, Doyle H, Furukawa H
University of Pittsburgh Medical Center, Pittsburgh Transplant Institute, Pennsylvania.
Clin Transpl. 1993:137-52.
FK506 undoubtedly improved the survival advantage of hepatic allotransplantation. Hepatic-intestinal and multivisceral transplantation has also become a feasible therapy for patients with combined intestinal and liver failure. With better understanding of the immunologic and metabolic aspects of allo- and xenotransplantation, further clinical attempts to transplant animal organs to humans may be considered with the hope for a better outcome in the very near future.
FK506无疑提高了肝同种异体移植的生存优势。肝肠联合移植和多脏器移植也已成为治疗合并肠肝衰竭患者的可行疗法。随着对同种异体移植和异种移植免疫及代谢方面的深入了解，或许可以考虑进一步开展将动物器官移植给人类的临床尝试，以期在不久的将来获得更好的治疗效果。
